US5245047A
(en)
*
|
1988-02-22 |
1993-09-14 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
JP3171931B2
(ja)
*
|
1992-06-02 |
2001-06-04 |
高砂香料工業株式会社 |
(R)−(−)−4−シアノ−3−ヒドロキシ酪酸t−ブチルエステル及びその製造方法
|
US5298627A
(en)
*
|
1993-03-03 |
1994-03-29 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
GB9512837D0
(en)
*
|
1995-06-23 |
1995-08-23 |
Zeneca Ltd |
reduction of ketone groups
|
HRP960312B1
(en)
|
1995-07-17 |
2001-10-31 |
Warner Lambert Co |
NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
|
US6087511A
(en)
*
|
1996-07-16 |
2000-07-11 |
Warner-Lambert Company |
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
|
US5908953A
(en)
*
|
1996-12-18 |
1999-06-01 |
Mitsubishi Chemical Corporation |
Method for producing (R)-4-cyano-3-hydroxybutyric acid lower alkyl ester
|
JPH11171850A
(ja)
*
|
1997-12-12 |
1999-06-29 |
Kanegafuchi Chem Ind Co Ltd |
酪酸エステル誘導体の製造方法
|
JP2001526256A
(ja)
|
1997-12-19 |
2001-12-18 |
ワーナー−ランバート・エクスポート・リミテッド |
1,3−ジオールの合成方法
|
EP1077212B1
(en)
*
|
1998-04-30 |
2003-08-20 |
Kaneka Corporation |
Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives
|
CA2305564C
(en)
|
1998-08-05 |
2008-06-17 |
Kaneka Corporation |
Process for the preparation of optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl]acetic acid derivatives
|
KR100313668B1
(ko)
|
1999-02-03 |
2001-11-26 |
박영구 |
(r)-4-시아노-3-히드록시부티르산 에스테르의 제조방법
|
HU227840B1
(en)
*
|
1999-05-06 |
2012-05-02 |
Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag |
Intermediates of atorvastatin synthesis and process for producing them
|
HUP0103788A3
(en)
*
|
1999-06-04 |
2003-05-28 |
Kaneka Corp |
Processes for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
|
US20040063969A1
(en)
*
|
1999-10-18 |
2004-04-01 |
Egis Gyogyszergyar Rt. |
Process for the preparation of amorphous atorvastatin calcium
|
JP2003517038A
(ja)
|
1999-12-17 |
2003-05-20 |
ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド |
結晶質アトルバスタチン三水和物半カルシウム塩の工場規模での製造方法
|
ES2258030T3
(es)
*
|
1999-12-17 |
2006-08-16 |
Pfizer Science And Technology Ireland Limited |
Procedimiento para producir atorvastatina calcio cristalina.
|
CN101250133B
(zh)
*
|
2000-05-31 |
2010-06-09 |
中国医学科学院药物研究所 |
(±)对氟-2-(2-甲基-丙酰基)-4-氧-n,3-二苯基-苯丁酰胺的合成方法以及其中的中间体
|
CN100368386C
(zh)
*
|
2000-05-31 |
2008-02-13 |
中国医学科学院药物研究所 |
(±)对氟-2-(2-甲基-丙酰基)-4-氧-n,3-二苯基-苯丁酰胺的合成方法以及其中的中间体
|
US6476235B2
(en)
*
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
EP1734034A3
(en)
|
2001-01-09 |
2007-01-03 |
Warner-Lambert Company LLC |
Carboxylic acid salts of beta-alanine esters or -amides
|
WO2002057229A1
(en)
*
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
SI20814A
(sl)
*
|
2001-01-23 |
2002-08-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Priprava amorfnega atorvastatina
|
SI20848A
(sl)
|
2001-03-14 |
2002-10-31 |
Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. |
Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
|
KR100609371B1
(ko)
|
2001-06-29 |
2006-08-08 |
워너-램버트 캄파니 엘엘씨 |
R-(r*,r*)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1h-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
|
CA2453211A1
(en)
|
2001-07-06 |
2003-01-16 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation
|
US7199261B2
(en)
|
2001-07-06 |
2007-04-03 |
Teva Pharmaceutical Industries Ltd |
Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
|
IL159050A0
(en)
|
2001-07-06 |
2004-05-12 |
Ciba Sc Holding Ag |
Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3, 5-dihydroy heptanoic acid derivatives, and intermediates thereof
|
JP4765217B2
(ja)
*
|
2001-07-30 |
2011-09-07 |
住友化学株式会社 |
(r)−4−シアノ−3−ヒドロキシブタン酸エステルの製造法
|
PL368647A1
(en)
|
2001-07-30 |
2005-04-04 |
Dr.Reddy's Laboratories Ltd. |
Crystalline forms vi and vii of atorvastatin calcium
|
US20030114497A1
(en)
*
|
2001-07-31 |
2003-06-19 |
Laman Alani |
Pharmaceutical compositions of amlodipine and atorvastatin
|
CA2456095C
(en)
*
|
2001-08-31 |
2010-05-11 |
Morepen Laboratories Ltd. |
An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
|
UA77990C2
(en)
*
|
2001-12-12 |
2007-02-15 |
|
Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
|
KR100849880B1
(ko)
*
|
2001-12-20 |
2008-08-01 |
주식회사 중외제약 |
광학활성 2-[6-(치환된 알킬)-1,3-디옥산-4-일]아세트산유도체의 신규 제조 방법
|
CZ296967B6
(cs)
|
2002-02-01 |
2006-08-16 |
Zentiva, A.S. |
Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
|
DE10212492B4
(de)
*
|
2002-03-21 |
2012-02-02 |
Daimler Ag |
Kolbenpumpe
|
DE60315308T2
(de)
*
|
2002-08-06 |
2007-12-20 |
Warner-Lambert Company Llc |
Verfahren zum herstell von 5-(4-fluorphenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäurephenylamid
|
US7125693B2
(en)
*
|
2002-08-09 |
2006-10-24 |
Codexis, Inc. |
Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives
|
CA2491051A1
(en)
*
|
2002-09-03 |
2004-03-18 |
Morepen Laboratories Limited |
Atorvastatin calcium form vi or hydrates thereof
|
HRP20020885B1
(en)
*
|
2002-11-11 |
2007-05-31 |
GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. |
SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
|
BRPI0409333A
(pt)
*
|
2003-04-14 |
2006-04-25 |
Warner Lambert Co |
processo para a preparação de fenilamida do ácido 5-(4-fluorofenil)-1-[2-((2r,4r)-4-hidróxi-6-oxo-tetrahid ro-piran-2-il)etil]-2-isopropil-4-fenil-1h-pirrol-3-carb oxìlico
|
US20050182125A1
(en)
*
|
2003-05-16 |
2005-08-18 |
Ambit Biosciences Corporation |
Pyrrole compounds and uses thereof
|
EP1626713A2
(en)
*
|
2003-05-16 |
2006-02-22 |
Ambit Biosciences Corporation |
Heterocyclic compounds and uses thereof
|
US20040248972A1
(en)
*
|
2003-05-16 |
2004-12-09 |
Ambit Biosciences Corporation |
Compounds and uses thereof
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
CA2539158A1
(en)
*
|
2003-09-17 |
2005-03-24 |
Warner-Lambert Company Llc |
Crystalline forms of ['r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
|
WO2005026107A1
(en)
*
|
2003-09-18 |
2005-03-24 |
Biocon Limited |
Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
|
EP1711489B1
(en)
*
|
2003-12-29 |
2012-12-26 |
LEK Pharmaceuticals d.d. |
Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
|
CA2456430A1
(en)
*
|
2004-01-28 |
2005-07-28 |
Brantford Chemicals Inc. |
Improved process for the preparation of amorphous atorvastatin calcium
|
PT1727795E
(pt)
|
2004-03-17 |
2012-04-11 |
Ranbaxy Lab Ltd |
Processo para a produção de atorvastatina cálcica na forma amorfa
|
US20070225353A1
(en)
*
|
2004-04-16 |
2007-09-27 |
Pfizer, Inc. |
Process for Forming Amorphous Atorvastatin
|
US7875731B2
(en)
|
2004-05-05 |
2011-01-25 |
Pfizer Inc. |
Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
|
HUE029911T2
(en)
*
|
2004-07-16 |
2017-04-28 |
Lek Pharmaceuticals |
Products of atorvastatin calcium oxidative degradation
|
CA2573771C
(en)
|
2004-07-20 |
2011-05-10 |
Warner-Lambert Company Llc |
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
|
JP2008510798A
(ja)
*
|
2004-08-27 |
2008-04-10 |
バイオコン・リミテッド |
非晶質アトルバスタチンカルシウムのための方法
|
KR20070067175A
(ko)
|
2004-10-28 |
2007-06-27 |
워너-램버트 캄파니 엘엘씨 |
무정형 아토르바스타틴 형성 방법
|
US20090208539A1
(en)
*
|
2004-11-22 |
2009-08-20 |
Adel Penhasi |
Stable atorvastatin formulations
|
EP1819319A1
(en)
*
|
2004-12-02 |
2007-08-22 |
Warner-Lambert Company LLC |
Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
|
JP2009507822A
(ja)
*
|
2005-09-09 |
2009-02-26 |
ファイザー・サイエンス・アンド・テクノロジー・アイルランド・リミテッド |
アトルバスタチン中間体の調製
|
US20090221839A1
(en)
*
|
2005-09-09 |
2009-09-03 |
Pfizer Inc. |
Preparation of an Atorvastatin Intermediate
|
US20090216029A1
(en)
*
|
2005-09-16 |
2009-08-27 |
Yatendra Kumar |
Process for the production of atorvastatin calcium in amorphous form
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
US8084488B2
(en)
*
|
2005-11-21 |
2011-12-27 |
Pfizer Inc. |
Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
|
EP1810667A1
(en)
|
2006-01-20 |
2007-07-25 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising amorphous atorvastatin
|
US7879585B2
(en)
|
2006-10-02 |
2011-02-01 |
Codexis, Inc. |
Ketoreductase enzymes and uses thereof
|
US20100113802A1
(en)
*
|
2006-11-02 |
2010-05-06 |
Cadila Pharmaceuticals Limited |
Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
|
WO2008059366A2
(en)
*
|
2006-11-17 |
2008-05-22 |
Pfizer Products Inc. |
Process for the preparation of cis-1, 3-diols from the corresponding beta-hydroxy ketones employing microbial ketone reductases
|
US7834195B2
(en)
*
|
2007-01-24 |
2010-11-16 |
Apotex Pharmachem Inc. |
Atorvastatin calcium propylene glycol solvates
|
US20110142883A1
(en)
*
|
2007-07-20 |
2011-06-16 |
Actavis Group Ptc Ehf |
Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
|
ES2523404T3
(es)
|
2007-08-03 |
2014-11-25 |
Pfizer Products Inc. |
Procedimiento de preparación de compuestos quirales
|
EP2075246A1
(en)
|
2007-12-27 |
2009-07-01 |
M. J. Institute of Research |
A process for preparation of amorphous form of atorvastatin hemi-calcium salt
|
US8115015B2
(en)
*
|
2009-01-26 |
2012-02-14 |
Cadila Healthcare Limited |
Process for the preparation of amorphous atorvastatin calcium
|
GB2474687A
(en)
*
|
2009-10-23 |
2011-04-27 |
Phoenix Chemicals Ltd |
A continuous process for the production of (R)-6-cyano-5-hydroxy-3-oxo-hexanoic acid tert-butyl ester (and derivatives)
|
KR20120011249A
(ko)
|
2010-07-28 |
2012-02-07 |
주식회사 경보제약 |
아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
|
WO2012032035A1
(en)
|
2010-09-09 |
2012-03-15 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Salts of 7-amino-3,5-dihydroxyheptanoic acid esters
|
WO2013004591A1
(en)
|
2011-07-01 |
2013-01-10 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Micronized crystals of atorvastatin hemicalcium
|
CN102766072B
(zh)
*
|
2012-08-07 |
2013-12-25 |
浙江宏元药业有限公司 |
一种制备阿托伐他汀钙手性侧链的方法
|
CN103145584B
(zh)
*
|
2013-03-05 |
2015-08-26 |
复旦大学 |
一种合成(3r,5r)-3,5-二羟基-6-氰基己酸酯的方法
|
CN106397241A
(zh)
*
|
2016-08-23 |
2017-02-15 |
杨锋 |
一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
|
CN108033899B
(zh)
*
|
2017-12-06 |
2020-04-10 |
浙江科技学院 |
一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法
|